GenomedS.A.

Research and experimental development in natural sciences and engineering

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2010-12-30
Share capital
132 130,10 PLN
Activity description

Genomed is a company that provides genetic diagnostics based on DNA sequencing and offers services for scientific research. It specializes in the analysis of any gene and also provides oligonucleotide synthesis. Additionally, Genomed is involved in personalized medicine and genome analysis.

Registered address
Ponczowa 12, 02-971 Warszawa, Poland
Website
genomed.plWebsite active
Phone
Social media
Electronic delivery address
AE:PL-75101-20426-SHSIA-21

Financials

Revenue history (in k)

Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.

Stock quotes

PLN 40.80
+1.20 (+3.03%)
40.0040.5041.0040.8010:0012:0014:0016:00
Open
PLN 41.00
High
PLN 41.00
Low
PLN 40.00
Volume
128
Avg. vol.
49.2
Market cap
PLN 53.91M
P/E ratio
16.72
EPS
PLN 2.44
Shares outstanding
1.32M
52-week
PLN 35.40 – 43.00
Dividend yield
3.68%
Dividend
PLN 1.50
Ex dividend date
Jul 6, 2026
ISIN
PLGNOMD00024
Exchange
NewConnect

Quarterly results

PeriodRevenueEBITNet profit
Q2 2026USD 1.93mUSD 165.32kUSD 123.99k
Q1 2026USD 1.83mUSD -4.05kUSD -13.24k
Q4 2025USD 2.20mUSD 512.81kUSD 408.84k
Q3 2025USD 2.00mUSD 434.46kUSD 358.11k

Results for Q3 2026:Nov 13, 2026

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue
This companyUSD 7.37mMedianUSD 133.91kAverageUSD 4.65m
Net profit
This companyUSD 853.73kMedianUSD -54.78AverageUSD 310.10k
Operating costs
This companyUSD 6.24mMedianUSD 175.72kAverageUSD 4.46m
Assets
This companyUSD 4.15mMedianUSD 254.44kAverageUSD 8.12m

Industry

Bank accounts

Registered as a VAT taxpayer on 2007-09-12. Active

Debt

No entries in the National Debtors Register (KRZ). No proceedings in KRZ

Real estate

TypeAmount
Buildings and premises
PLN 20,226

MSiG notices

Publication dateEvent
Feb 9, 2017Bankruptcy notice
Oct 5, 2012Commercial Companies Code notice

Public aid

10 public aid cases recorded, with a total value of $857,098.

PurposeGross amount
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$204.6K
De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier)
$2,116
De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier)
$1,566

European Funds

ProjectEU co-financing
Opracowanie metod nieinwazyjnej diagnostyki genetycznej i profilaktyki chorób nowotworowych - płynnej biopsji.
$525.3K

Tenders

77 tenders recorded as contractor: 57 national ($1,297,469) and 20 EU ($7,695,975).

SubjectAmount
Dostawa odczynników chemicznych na potrzeby Centralnego Laboratorium Głównego Inspektoratu Ochrony Roślin i Nasiennictwa - ogłoszenie dotyczy części 26-39.
$125.3K
Usługa sekwencjonowania NGS (ang. Next Generation Sequencing)
$864.3K
Dostawa odczynników chemicznych do badań i analiz laboratoryjnych dla Wojewódzkiego Inspektoratu Weterynarii w Gdańsku - 11 części
$89,888

Public sector contracts

Genomed is the contractor in 354 public sector contracts, worth PLN 1.03m in total. They were signed with 64 public buyers.

Public buyerValue
Uniwersytet Im. Adama Mickiewicza w PoznaniuPLN 1,325
Szkoła Główna Gospodarstwa Wiejskiego w WarszawiePLN 302.10
Uniwersytet Marii Curie-SkłodowskiejPLN 1,220
Uniwersytet Marii Curie-SkłodowskiejPLN 528.46
Uniwersytet Marii Curie-SkłodowskiejPLN 3,659

National Health Fund (NFZ) contracts

Genomed has been an NFZ healthcare provider since 2011. In 2012 it is performing 1 contract worth USD 2.16k. All its contracts were worth USD 12.99k in total.

NFZ contract value by year (in k USD)

Type of careNFZ branchContractsValue in 2012
Ambulatoryjna opieka specjalistycznamazowieckie1USD 2.16k

Trademarks

Genomed holds 8 active trademarks registered with the Polish Patent Office. The first mark was filed in 2009.

MarkProtected until
ParentoNov 10, 2031
genome23Apr 23, 2030
infanoMar 18, 2030
MIMOMar 18, 2030
brovar VARIANT BROWSERMar 18, 2030

Regulatory authorisations

AuthorityTypeStatus
BDO register entry Active

Authorized Representatives

Andrzej Henryk Pałucha – Management Board Member
Anna Boguszewska Chachulska – President of the Management Board
Anna Piotrowska Mietelska – Management Board Member
Łukasz Brejnakowski – Management Board Member
Iwona Wach – Management Board Member

Manner of representation

The company may be represented by two members of the management board acting jointly or by a member of the management board acting with a commercial proxy.

Supervisory board

Mieczysław Andrzej Prószyński – Supervisory Board Member
Tomasz Bykowski – Supervisory Board Member
Grzegorz Piotr Gromada – Supervisory Board Member
Jakub Józef Swadźba – Supervisory Board Member
Piotr Mariusz Skowron – Supervisory Board Member

Beneficial owners

Person

Competitors

Name
Polpharma BiologicsS.A.
Scope FluidicsS.A.
BiotechnaS.A.
IntodnaS.A.
Read-GeneS.A.
Eurxsp. z o.o.
Medsource Polskasp. z o.o.
FamicordtxS.A.
BiokineticaS.A.
Saventic Healthsp. z o.o.

Change history

DateEvent
2015-04-24PKD change
2011-04-12Share capital change
2010-12-30Entered in the register

FAQ

Last updated: 2026-10-04